MMN/P3a deficits in first episode psychosis: Comparing schizophrenia-spectrum and affective-spectrum subgroups

被引:83
作者
Kaur, Manreena [1 ]
Battisti, Robert A. [1 ]
Ward, Philip B. [2 ,3 ]
Ahmed, Arnab [1 ]
Hickie, Ian B. [1 ]
Hermens, Daniel F. [1 ]
机构
[1] Univ Sydney, Clin Res Unit, Brain & Mind Res Inst, Sydney, NSW 2006, Australia
[2] Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia
[3] Liverpool Hosp, SW Sydney Local Hlth Network, Schizophrenia Res Unit, Liverpool, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
First-episode; Schizophrenia; Affective; Mismatch negativity; Cognition; Psychosocial; MISMATCH NEGATIVITY GENERATION; 1ST-EPISODE PSYCHOSIS; REDUCTION; MEMORY; P300; MMN; DYSFUNCTION; SYMPTOMS; P3A; EEG;
D O I
10.1016/j.schres.2011.03.025
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Reduced mismatch negativity (MMN) and P3a amplitudes are neurophysiological biomarkers for schizophrenia that index deviance detection and the orienting response, respectively. First-episode psychosis (FEP) patients show reduced amplitudes of the 'MMN/P3a complex', but it is unclear whether this occurs across the FEP spectrum. Methods: Fifty-three young people (17-36 years) were assessed: 17 FEP affective-spectrum (bipolar disorder with psychotic features and major depressive disorder with psychotic features), 18 FEP schizophrenia-spectrum (schizophrenia, schizoaffective disorder, and schizophreniform disorder), and 18 healthy controls. MMN/P3a was acquired during a two-tone, auditory paradigm with 8% duration deviants. Clinical, psychosocial and neuropsychological assessments were also undertaken. Results: FEP schizophrenia- and FEP affective-spectrum showed significantly reduced fronto-central MMN and central P3a amplitudes compared to controls. FEP subgroups also showed significantly poorer cognitive and psychosocial functioning. The combined FEP sample showed significant correlations between fronto-central MMN amplitudes and cognitive measures. Discussion: FEP schizophrenia-spectrum and FEP affective-spectrum were similarly impaired in two biomarkers for schizophrenia. FEP subgroups showed impairments in fronto-central MMN consistent with chronic patients. Similarly, both subgroups showed reductions in P3a; although the affective subgroup showed an 'intermediate' frontal response. These findings suggest that FEP patients with both affective and schizophrenia spectrum diagnoses share common neurobiological disturbances in deviance detection/orienting processes in the early phase of illness. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 44 条
  • [1] Epidemiology of first-episode psychosis: Illustrating the challenges across diagnostic boundaries through the Cavan-Monaghan study at 8 years
    Baldwin, P
    Browne, D
    Scully, PJ
    Quinn, JF
    Morgan, MG
    Kinsella, A
    Owens, JM
    Russell, V
    O'Callaghan, E
    Waddington, JL
    [J]. SCHIZOPHRENIA BULLETIN, 2005, 31 (03) : 624 - 638
  • [2] CATTS SV, 1995, AM J PSYCHIAT, V152, P213
  • [3] First M.B., 2001, Structured Clinical Interview for DSM-IV Axis I Disorders
  • [4] The novelty P3: an event-related brain potential (ERP) sign of the brain's evaluation of novelty
    Friedman, D
    Cycowicz, YM
    Gaeta, H
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2001, 25 (04) : 355 - 373
  • [5] GOLDMAN HH, 1992, AM J PSYCHIAT, V149, P1148
  • [6] Deconstructing psychosis with human brain imaging
    Gur, Raquel E.
    Keshavan, Matcheri S.
    Lawrie, Stephen M.
    [J]. SCHIZOPHRENIA BULLETIN, 2007, 33 (04) : 921 - 931
  • [7] Hamilton M., 1967, Br J Soc Clin Psychol, V6, P278, DOI 10.1111/j.2044-8260.1967.tb00530.x
  • [8] Impaired MMN/P3a complex in first-episode psychosis: Cognitive and psychosocial associations
    Hermens, Daniel F.
    Ward, Philip B.
    Hodge, M. Antoinette Redoblado
    Kaur, Manreena
    Naismith, Sharon L.
    Hickie, Ian B.
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2010, 34 (06) : 822 - 829
  • [9] Prefrontal gray matter volume reduction in first episode schizophrenia
    Hirayasu, Y
    Tanaka, S
    Shenton, ME
    Salisbury, DF
    DeSantis, MA
    Levitt, JJ
    Wible, C
    Yurgelun-Todd, D
    Kikinis, R
    Jolesz, FA
    McCarley, RW
    [J]. CEREBRAL CORTEX, 2001, 11 (04) : 374 - 381
  • [10] Neurophysiological biomarkers for drug development in schizophrenia
    Javitt, Daniel C.
    Spencer, Kevin M.
    Thaker, Gunvant K.
    Winterer, Georg
    Hajos, Mihaly
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (01) : 68 - 83